ArticleFrontiers in oncology2025
Bringing value to cancer research.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This article argues for incorporating a broader definition of "value" into cancer clinical trials. Current trials primarily focus on efficacy and safety, neglecting patient-reported outcomes (PROs) such as quality of life, financial toxicity, and time burden, as well as cost-effectiveness. We propose a novel framework integrating oncologic outcomes, PROs, and cost analyses. We also propose a multidimensional visual tool, such as a radar chart, to facilitate better-informed, value-based shared decision-making. This requires a collaborative approach, involving stakeholders in defining value metrics. While acknowledging challenges such as increased administrative burden and data interpretation complexities, a comprehensive framework can substantially improve patient-centered cancer care. The ultimate goal is to standardize value assessment in cancer research, leading to more equitable and effective care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.